1
|
Hamidi A, Kreeftenberg H, V D Pol L, Ghimire S, V D Wielen LAM, Ottens M. Process development of a New Haemophilus influenzae type b conjugate vaccine and the use of mathematical modeling to identify process optimization possibilities. Biotechnol Prog 2016; 32:568-80. [PMID: 26821825 DOI: 10.1002/btpr.2235] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2015] [Revised: 12/03/2015] [Indexed: 01/15/2023]
Abstract
Vaccination is one of the most successful public health interventions being a cost-effective tool in preventing deaths among young children. The earliest vaccines were developed following empirical methods, creating vaccines by trial and error. New process development tools, for example mathematical modeling, as well as new regulatory initiatives requiring better understanding of both the product and the process are being applied to well-characterized biopharmaceuticals (for example recombinant proteins). The vaccine industry is still running behind in comparison to these industries. A production process for a new Haemophilus influenzae type b (Hib) conjugate vaccine, including related quality control (QC) tests, was developed and transferred to a number of emerging vaccine manufacturers. This contributed to a sustainable global supply of affordable Hib conjugate vaccines, as illustrated by the market launch of the first Hib vaccine based on this technology in 2007 and concomitant price reduction of Hib vaccines. This paper describes the development approach followed for this Hib conjugate vaccine as well as the mathematical modeling tool applied recently in order to indicate options for further improvements of the initial Hib process. The strategy followed during the process development of this Hib conjugate vaccine was a targeted and integrated approach based on prior knowledge and experience with similar products using multi-disciplinary expertise. Mathematical modeling was used to develop a predictive model for the initial Hib process (the 'baseline' model) as well as an 'optimized' model, by proposing a number of process changes which could lead to further reduction in price. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 32:568-580, 2016.
Collapse
Affiliation(s)
- Ahd Hamidi
- Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | - Hans Kreeftenberg
- Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | - Leo V D Pol
- Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720 AL Bilthoven, The Netherlands
| | - Saroj Ghimire
- Dept. of Biotechnology, Delft University of Technology, The Netherlands
| | | | - Marcel Ottens
- Dept. of Biotechnology, Delft University of Technology, The Netherlands
| |
Collapse
|
2
|
Brgles M, Bonta M, Šantak M, Jagušić M, Forčić D, Halassy B, Allmaier G, Marchetti-Deschmann M. Identification of mumps virus protein and lipid composition by mass spectrometry. Virol J 2016; 13:9. [PMID: 26768080 PMCID: PMC4712546 DOI: 10.1186/s12985-016-0463-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Accepted: 01/05/2016] [Indexed: 01/19/2023] Open
Abstract
Background Mumps virus is a negative-sense, single stranded RNA virus consisting of a ribonucleocapsid core enveloped by a lipid membrane derived from host cell, which causes mumps disease preventable by vaccination. Since virus lipid envelope and glycosylation pattern are not encoded by the virus but dependent on the host cell at least to some extent, the aim of this work was to analyse L-Zagreb (L-Zg) mumps virus lipids and proteins derived from two cell types; Vero and chicken embryo fibroblasts (CEF). Jeryl Lynn 5 (JL5) mumps strain lipids were also analysed. Methods Virus lipids were isolated by organic phase extraction and subjected to 2D-high performance thin layer chromatography followed by lipid extraction and identification by matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS). Virus samples were also subjected to gel electrophoresis under denaturating conditions and protein bands were excised, in-gel trypsinized and identified by MS as well as tandem MS. Results Results showed that lipids of both mumps virus strains derived from Vero cells contained complex glycolipids with up to five monosaccharide units whereas the lipid pattern of mumps virus derived from CEF was less complex. Mumps virus was found to contain expected structural proteins with exception of fusion (F) protein which was not detected but on the other hand, V protein was detected. Most interesting finding related to the mumps proteins is the detection of several forms of nucleoprotein (NP), some of which appear to be C-terminally truncated. Conclusions Differences found in lipid and protein content of mumps virus demonstrated the importance of detailed biochemical characterization of mumps virus and the methodology described here could provide a means for a more comprehensive quality control in vaccine production. Electronic supplementary material The online version of this article (doi:10.1186/s12985-016-0463-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Marija Brgles
- University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000, Zagreb, Croatia. .,Center of Excellence for Viral Immunology and Vaccines, CERVirVac, Rijeka, Zagreb, Croatia.
| | - Maximilian Bonta
- Vienna University of Technology, Institute of Chemical Technologies and Analytics, A-1060, Vienna, Austria.
| | - Maja Šantak
- University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000, Zagreb, Croatia. .,Center of Excellence for Viral Immunology and Vaccines, CERVirVac, Rijeka, Zagreb, Croatia.
| | - Maja Jagušić
- University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000, Zagreb, Croatia. .,Center of Excellence for Viral Immunology and Vaccines, CERVirVac, Rijeka, Zagreb, Croatia.
| | - Dubravko Forčić
- University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000, Zagreb, Croatia. .,Center of Excellence for Viral Immunology and Vaccines, CERVirVac, Rijeka, Zagreb, Croatia.
| | - Beata Halassy
- University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Rockefellerova 10, HR-10000, Zagreb, Croatia. .,Center of Excellence for Viral Immunology and Vaccines, CERVirVac, Rijeka, Zagreb, Croatia.
| | - Günter Allmaier
- Vienna University of Technology, Institute of Chemical Technologies and Analytics, A-1060, Vienna, Austria.
| | | |
Collapse
|